GELATINASES OF THROMBOCYTES, THEIR ROLE IN METASTASIS AND PROGNOSIS IN GASTRIC CANCER
Keywords:
thrombocytes, matrix metalloproteinases, gastric cancer, survival of patients.Abstract
Summary. It is known that the protein profile of circulatory thrombocytes represents motion of tumor process, that is why the search of possibilities of the use of
characteristics of thrombocytes and producted by them
matrix metalloproteinases (MMP) as markers of tumor
growth and for prognostication of therapeutic answer of
tumor or progress of disease seems expedient. Aim: to define correlations between the amount of thrombocytes,
the activity of producted by them gelatinases (MMP-2
and -9) and by clinicopathologic characteristics of tumor process, tumor cells dissemination in bone marrow
and by survivability of patients with the gastric cancer (GC). Object and methods: the specimens of blood
thrombocytes of 89 patients with primary GC (stages of
I — 13%, II — 34%, III — 35%, IV — 18%) were investigated. It were used zymography in a polyacrilamide
gel, immunohistochemical, statistical methods. Results:
on the late stages of GC the amount of blood thrombocytes grows in comparing to the initial stages of disease
on 74%, total activity of both gelatinases of thrombocytes on the late stages of GC, opposite, goes down in
comparing to initial indices 40.5%. Activity of thrombocytes MMP-9 back correlate with the category of М.
For all investigated patients, and also for the patients of
category of М0
, activity of MMP-9 in default of disseminated tumor cells (DTC) in bone marrow was almost
2.0 and 1.7 times, respectively, more subzero from such
at presence of DTC. DTC in bone marrow of patients of
category of М0
were registered at 1.6 times more thrombocytes, than in default of DTC. An amount of thrombocytes
in blood of patients that was below 2.0•105
/mm3
, live for
certain longer and have relatively a less risk of death
from progress of disease. At high activity of MMP-9 lifespan of both all inspected patients and patients of category of М0
, for certain is less, and relative risk higher, than at subzero activity of this gelatinases. Conclusions: amount of thrombocytes in blood and activity of
them MMP-9 are factors, that is related to the stage of
GC, metastasis and settling of DTC in bone marrow can
be used in control of disease for patients on GC with the
aim of correction of antitumoral therapy.
References
Ганусевич ИИ. Роль матриксных металлопротеиназ (ММП) при злокачественных новообразованиях. Характеристика ММП, регуляция их активности, прогностическое значение. Онкология 2010; 12 (1): 10–6.
Kubben F, Sier C, Duijn W, et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006; 94: 1035–40.
Peña S. Matrix metalloproteases as molecular markers in gastric cancer.Med Clin 2010; 134 (3): 123–6.
Wu CY, Wu MS, Chiang EP, et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 2007; 13: 2054–60.
Chu D, Zhang Z, Li Y, et al. Matrix metalloproteinase-9 is associated with disease free survival and overall survival in patients with gastric cancer. Int J Cancer 2011; 129: 887 — 95.
Mimori K, Fukagawa T, Kosaka Y, at al. A large-scale study of MT1-MMP as a marker for isoleted tumor cells in peripheral blood and bone marrow in gastric cancer cases. An Surg Oncol 2008; 15(10): 2934–42.
Kassenbrock K, Plaks V, Werb Z. Matrix metalloproteinases regulators of the tumor microenvironment. Cell 2010; 141: 52–67.
Noel A, Guttierez-Fernandez A, Sounni NE, et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Frontier Pharmacol 2012; 3; 1–9.
Orlichenko LS, Radisky DC. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis 2008; 25: 593–600.
Stangerand BZ, Kahn ML. Platelets and tumor cells: a new form of border control. Cancer Cell 2013; 24 (8); 9–11.
Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178–85.
Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011; 20: 576–90.
Ганусевич ИИ. Роль матриксных металлопротеиназ (ММП) при злокачественных новообразованиях. Участие ММП в ангиогенезе, инвазии и метастазировании опухолей. Онкология 2010; 12 (2): 108–17.
Naumov GN, Bender E, Zurakowski D, Kang SY, et al. A model of human tumor dormancy: an angiogenics witch from then on angiogenic phenotype. J Natl Cancer Inst 2006; 98: 316–25.
Almog N, Ma L, Raychowdhury R, Schwager C, et al. Transcriptionals witch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009; 69: 836–44.
Mohle R, Green D, Moore MA, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663–8.
Qureshi AA, Karpen CW, Qureshi N, et al. Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries. Lipids Health Dis 2011; 10: 58–71.
De Clerk YA, Perez N, Shimada H, et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701–8.
Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004;
: 34–44.
Seibert V, Wiesner A, Buschmann T, Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and Protein Chip technology in proteomics research. Pathol Res Pract 2004; 200: 83–94.
Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008; 8 (8): 1247–55.
Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123–34.
Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood 2015; 126 (5): 582–8.
Orellana R, Kato S, Erices R, et al. Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer 2015; 15: 290.
Labelle M, BegumS, O. HynesR. Platelets guide the formation of early metastatic niches. Current Issue 2011; 11 (30):
–61.
Ware J. Fragmenting the platelet to reduce metastasis. Blood 2012; 120 (14): 2779–80.
Domínguez I, Crippa S, Thayer SP, Hung YP. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg 2008; 32 (6): 1051–6.
Schwarz RE. Platelet counts and prognosis of pancreatic cancer. Lancet 1999; 353 (9170): 2158–9.
Yu D, Liu B, Zhang L, Du K. Platelet count predicts prognosis in operable non-small cell lung cancer. Exp Ther Med 2013; 5 (5): 1351–4.
Inagaki N, Kibata K, Tamaki T, et al. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer 2014; 83 (1): 97–101.
Ishizuka M, Nagata H, Takagi K, et al. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer 2013; 109: 401–47.
Hwang SG, Kim KM, Cheong JH, et al.Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol 2012; 38: 562–7.
Wang L, Huang X, Chen Y, et al. Prognostic value of TP/ PD-ECGF and thrombocytosis in gastric carcinoma. Eur J Surg Oncol 2012; 38: 568–73.
Hu C, Chen R, Chen W, et al. Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer. Exp Ther Med 2014; 8: 125–32.
Ishizuka M, Oyama Y, Abe A, et al. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients undergoing surgery for gastric cancer. J Surg Oncol 2014; 110: 935–41.
Li FX, Wei LJ, Zhang H, et al. Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer. Asian Pac J Cancer Prev 2014; 15: 6511–17.
